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EFFECTIVE RNA LOADING OF CD34 DERIVED DENDRITIC CELLS FOR
ADOPTIVE IMMUNOTHERAPY
Hsu, A.K.W., Kerr, B.M., Allan, C.P., Turtle, C.J., Hart, D.N.J.,
Rice, A.M. Mater Medical Research Institute, South Brisbane, Queens-
land, Australia.
A successful immunotherapeutic strategy for the treatment of
relapsed Acute Lymphoblastic Leukemia (ALL) post stem cell
transplantation requires the optimisation of multiple parame-
ters. The aim of this project was to optimise RNA loading
conditions into dendritic cells (DC) for eventual induction of
leukemia speciﬁc cytotoxic T lymphocyte (CTL) responses. We
hypothesized that electroporation would be an efﬁcient tech-
nique with which to introduce IVT-RNA into cord blood
CD34derived DC. The aims of this project were to: 1) to
optimise variables affecting transfection efﬁciency (using IVT-
enhanced green ﬂuorescent protein (eGFP) mRNA as a model
antigen), 2) optimise variables affecting cell viability, 3) deter-
mine the optimal day of RNA loading and 4) show that the
electroporated CD34 derived DC were functional. We de-
signed experiments to investigate the effects of cuvette size, cell
concentration, voltage, capacitance and electroporation medium
on the viability and transfection efﬁciency of CD34derived
DC. Additionally, we investigated factors pre and post electro-
poration including: incubation times and exposure of cells to
different temperature environments that can inﬂuence viability
and GFP uptake by CD34derived DC. Using our optimal
conditions we achieved 91% GFP transfection efﬁciency with
90% cell viability, and 94% of Lin-CD11cHLA-DR DC have
taken up RNA. A crucial ﬁnding was the effect of temperature
on cell membranes, signiﬁcantly affecting transfection efﬁ-
ciency and cell survival. Cells will take up more RNA and
survive better in a warm (37oC) environment compared to room
temperature or ice. Transfection efﬁciency of CD34derived
DC electroporated on day 9 of culture was consistently higher
that that observed on day 7 of culture. Interestingly, electropo-
ration did not further upregulate activation markers on
CD34derived DC. CD34derived DC electroporated with Flu
Matrix protein RNA under the optimised conditions are able to
present antigen and be killed by ﬂu CTL clones. In conclusion,
we have developed an efﬁcient and safe electroporation proce-
dure that results in functional RNA loaded CD34derived DC
that can now be used to stimulate CTL for adoptive immuno-
therapy.
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RAPAMYCIN-GENERATED CD4, TH2 CELLS MODULATE GRAFT-VER-
SUS-HOST REACTION VIA AN IL-4 DEPENDENT MECHANISM
Foley, J., Jung, U., Henrikson, R., Fowler, D. National Cancer Insti-
tute, NIH, Bethesda, MD.
Augmentation of T cell replete allografts with donor Th2 cells
represents an approach to achieve a balance of type I and type II
cytokine immunity post-BMT for mediation of a graft-versus-
tumor (GVT) effect with regulation of graft-versus-host disease
(GVHD). We have recently found that in vitro usage of high-
dose rapamycin (10 uM) generates murine Th2 cells that po-
tently inhibit allograft CD4 and CD8 T cell acquisition of
IFN-based allospeciﬁcity, promote type II cytokine production
in vivo, and reduce GVHD while preserving a component of
GVT effect against allogeneic breast cancer cells. Because ra-
pamycin-generated Th2 cells secreted reduced IL-4 and greatly
reduced IL-5, IL-10, and IL-13 relative to control Th2 cells, we
hypothesized that this population might regulate graft-versus-
host reaction (GVHR) through a non-IL-4 mechanism. To
address this possibility, CD4 T cells from wild-type (wt) or
IL-4 knock-out (IL-4 KO) donor C57Bl/6 mice were co-stim-
ulated with anti-CD3, anti-CD28 coated beads in media sup-
portive of Th2 differentiation (IL-4, IL-2, IL-7) either
without (“Th2”) or with rapamycin (10 uM; “Th2.rapa”). Th2
or Th2.rapa cells generated from IL-4 KO donors were indeed
deﬁcient in IL-4 secretion, but otherwise secreted a similar
Th2-type cytokine pattern as Th2 or Th2.rapa cells expanded
from wt donors. As shown (Table), relative to wt Th2 cells, wt
Th2.rapa cells expanded greater in vivo after semi-allogeneic
BMT (B6-into-CB6F1; 1050 cGy XRT; BMT supplemented
with 20 x 106 donor GVHR-inducing T cells) and more potently
inhibited allograft CD4 and CD8 T cell acquisition of IFN-
allospeciﬁcity; Th2.rapa cells also yielded a more dramatic shift
toward type II cytokine secretion post-BMT (increased IL-4,
IL-5, IL-10, and IL-13; each p  0.05). In marked contrast,
IL-4 deﬁcient Th2 or Th2.rapa cells failed to modulate GVHR,
as such recipients had levels CD4 and CD8 IFN-allospeci-
ﬁcity similar to the GVHR control group. In conclusion, rela-
tive to control Th2 cells, rapamycin generated donor Th2 cells
have an increased capacity to inhibit GVHR; although Th2.rapa
cells secrete reduced IL-4 and greatly reduced IL-5, IL-10, and
IL-13 in vitro, their ability to induce these cytokines in vivo
post-BMT is signiﬁcantly increased. Both Th2 and Th2.rapa
cells are fully dependent upon IL-4 secretion for their inhibition
of GVHR, and as such, these cells operate through a conven-
tional Th2-type mechanism.
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RISK FACTORS OF DEVELOPING ACUTE GRAFT-VERSUS-HOST DISEASE
(AGVHD) AFTER HLA-MATCHED UNRELATED DONOR (MUD) TRANS-
PLANTATION -IMPORTANCE OF MAINTAINING THE BLOOD LEVEL OF
TACROLIMUS EARLY AFTER TRANSPLANTATION
Okamoto, S., Iguchi, T., Mori, T., Watanabe, R., Aisa, Y., Shimizu, T.,
Yokoyama, A., Ikeda, Y. Division of Hematology, Keio University School
of Medicine, Tokyo, Japan.
The aim of this study was to identify risk factors for moderate to
severe AGVHD in adults after MUD marrow transplantation and
prophylaxis with tacrolimus and methotrexate (MTX). Seventy ﬁve
adults with leukemia or marrow failure received a myeloablative
preparative regimen and unmanipulated bone marrow graft from a
HLA-serologically matched (50 allele match, 25 allele mismatch)
unrelated donor. Tacrolimus (0.03 mg/kg/day) was given by con-
tinuous infusion from day -1 and the dose was adjusted to maintain
whole blood steady state or trough levels between 10 and 20 ng/ml.
MTX was administered on days 1,3,6, /-11. 36 (48%) patients
Table. Th2.rapa Cells Potently Inhibit GVHR Via an
IL-4–dependent Mechanism
Total # Donor T Cellsb
# IFN- Allospecific
Cellsc
Trx Groupa CD4 CD8 CD4 CD8
1 (no Th2) 5.2  0.5 17.4  1.9 1.5  0.3 2.5  0.6
2 (Th2 wt) 15.0  2.1* 11.4  1.2* 0.9  0.2* 0.2  0.1*
3 (Th2 IL-4
KO) 15.1  1.5* 24.0  1.6† 1.5  0.2† 5.1  0.9†
4 (Th2.rapa) 35.6  2.5* 6.4  0.2* 0.4  0.1* 0.1  0.1*
5 (Th2.rapa
IL-4 KO) 25.6  1.2* 10.1  1.3† 1.9  0.5† 2.1  0.5†
aCB6F1 mice were lethally irradiated (1050 cGy; n  5 per trx group). Each mouse
received B6 marrow (1  106) and B6 T cells (20  106). Groups 2-5 received in
vitro–generated donor Th2 cells (10  106 cells) that were generated from wild-type or
IL-4 KO donors, and were generated either without or with rapamycin (10 M).
bAbsolute # of donor CD4 and CD8 splenic T cells was enumerated at day 7 post BMT
using ﬂow cytometry. cDay 7 splenic T cells were stimulated in vitro with CB6F1
dendritic cells, and the # of CD4 and CD8 cells producing IFN-	 was determined by
cytokine capture ﬂow cytometry. *Value is statistically different (P  0.05) relative to the
GVHR control group (group 1). †Value for the IL-4 KO group is statistically different
from the result obtained with the respective wild type Th2 or Th2.rapa cohort (that is,
group 5 vs. group 4 and group 3 vs. group 2).
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developed grade II to IV AGVHD, and 15 (20%) developed grades
III to IV AGVHD. In univariate analysis, advanced diseases, donor
and recipient age were signiﬁcant risk factors for developing
AGVHD. On the other hand, omitting day 11 MTX, Class I
and/or Class II HLA allele disparities, CMV seropositivity, or sex
mismatch were not identiﬁed as risk factors. The mean blood level
of tacrolimus during the ﬁrst three weeks were signiﬁcantly lower
in those who developed grade II to IV or III to IV AGVHD than
that of patients who did not (17.5 vs.15..8 vs.15.3 p  0.007, p 
0.015), and the level 15ng/ml during the third week was associ-
ated with the occurrence of moderate or severe AGVHD(p 
0.023). In multivariate analysis, only the mean concentration of
tacrolimus remained as a risk factor to develop moderate to severe
AGVHD. The incidence of nephrotoxicity (doubling of serum
creatinine) or hyperglycemia (BS 200mg/dl) did not signiﬁcantly
correlate with the mean blood level of tacrolimus until three weeks
after transplant; however, the incidence of those events signiﬁ-
cantly correlated with the tacrolimus blood level of a week before
the events thereafter (p  0.0001). These data suggest the impor-
tance of maintaining tacrolimus blood level above 15 ng/ml during
the ﬁrst three weeks after transplantation to optimize the efﬁcacy
while minimize its side effects.
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THERAPEUTIC ANTIBODY MEDIATED DEPLETION OF ACTIVATED DEN-
DRITIC CELLS AND THE PREVENTION OF GRAFT VERSUS HOST DIS-
EASE
Wilson, J., Rice, A.M., Hart, D.N.J., Munster, D.J. Mater Medical
Research Institute, South Brisbane, Queensland, Australia.
Graft versus host disease (GVHD) is the most common compli-
cation of haemopoietic stem cell transplantation and contributes
signiﬁcantly to the morbidity and mortality of the procedure.
Current GVHD prevention targets donor T lymphocytes involved
in recipient tissue destruction. This strategy is associated with long
term immunosuppression, loss of the graft versus leukaemia effect
and graft failure. Dendritic cells (DCs) are a leucocyte population
of antigen presenting cells (APC) which, when activated, stimulate
the donor T lymphocyte attack in GVHD and as such, represent a
possible alternative therapeutic target. To investigate the effect of
DC depletion in GVHD, we used an established mouse-human
chimeric model of GVHD in which human T lymphocytes are
known to be effector cells. Brieﬂy, severe combined immunodeﬁ-
cient (SCID) mice were injected with whole or depleted human
PBMC, causing a GVHD-like syndrome that was measured by
mouse survival and human cell engraftment. Preliminary data sug-
gests that human and not murine APC are required to induce
GVHD. Contrary to a previous report, human B lymphocytes do
not appear to contribute to GVHD in the mouse. We found that
SCID mice injected with human PBMC that had been depleted, in
vitro, of activated DC with CMRF-44 antibody survived longer
than undepleted controls (p  0.05). Work is currently under-
way to achieve and assess in vivo depletion of human DC in this
model.
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AN EFFICACY OF INTERFERON- (IFN-) AND INTERLEUKIN-2 (IL-2)
IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES RELAPSE-
PERSISTENCE-PROGRESSION AFTER THE ALLOGENEIC NONMYELOAB-
LATIVE STEM CELL TRANSPLANTATION (NSCT)
Raida, L., Faber, E., Papajik, T., Vlachova, S., Jarosova, M. Hemato-
Oncology Dpt., University Hospital, Olomouc, Czech Republic.
Introduction: GvL reaction belongs to the key mechanisms of
tumour control. Its realisation depends on following circum-
stances: 1) the tumour cells express antigens identiﬁed by donor
T-cells, 2) the engraftment of donor T-cells, 3) the proliferation
activity of tumour and 4) its burden. IFN- and IL-2 belong to the
cytokines allowing to enhance the GvL effect, unfortunately, as
well as the risk of GvHD. We present an experience with the
IFN- and IL-2 administration after allogeneic NSCT in 3 pa-
tients suffering from the different haematological malignancies. 1st
case: 45-years old male with refractory peripheral T-cell lym-
phoma underwent NSCT (ﬂudarabinbusulphanATG) from
MUD. He achieved the complete donor chimerism and the CR of
disease. A prophylactic immunosupression was stopped on day
100 without the development of GvHD. 10 months after NSCT
the skin relapse of lymphoma was proven and the treatment with
cytokines was initiated. IL-2 (3 MIU t.i.w.) has been added after 3
weeks of IFN- (3 MIU t.i.w.) only. At least 25% resolution of skin
involvement was observed 3 months after the start of cytokines
administration. 2nd case: 49-years old male with B-CLL and the
transformation to diffuse large cell lymphoma was allografted
from HLA-identical sibling after conditioning ﬂudarabin and cy-
clophosphamide. He developed the extensive chronic GvHD that
has completely resolved on corticosteroids and CSA and this
immunosuppression was stopped 10 months after NSCT. 11
months after NSCT the patient developed the relapse of dis-
ease with lymph nodes bulk and bone marrow involvement. The
treatment with IFN- was started. 10 doses of 3 MIU applied in
2 months have led to the CR without the need of IL-2 addition.
3rd case: 44-years old male with refractory AML was allografted
from HLA-identical sibling after reduced intensity condition-
ing (ﬂudarabinARA-Cidarubicin). The bone marrow aspirate
evaluation revealed 30% of leukemic blasts on day 14. CSA
was stopped and 5 doses of IFN- (3 MIU) and 3 ones of IL-2 (6
MIU) were administered. The last myelogram evaluation on day
56 proved the reduction of blasts to 11%. Since the start of
cytokines no GvHD has developed in these 3 patients, yet.
Conclusion: The presentation of the 3 cases of different haema-
tological malignancies treated with IFN- and IL-2 but without
any DLI demonstrates the efﬁcacy of this approach that might
become a possible way how to control some malignancies after
NSCT.
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7/ DONOR T CELLS CAUSE LESS GRAFT-VERSUS-HOST DISEASE
WHILE PRESERVING GRAFT-VERSUS-TUMOR ACTIVITY
Waldman, E.D., Alpdogan, O., Petrovic, A., Eng, J.M., Hubbard, V.,
Kochman, A., Muriglan, S., van den Brink, M.R.M. Memorial Sloan-
Kettering Cancer Center, New York, NY.
Recent studies have demonstrated the important role of T cell
homing and its regulation by integrins, chemokine receptors and
ligands in the pathogenesis of acute graft-versus-host disease
(GVHD). Studies by others and by us have suggested that the 47
integrin (LPAM) plays a role in the homing of alloreactive T cells
to the gut and the development of intestinal GVHD. We have
previously demonstrated, using 47 positively and negatively
sorted T cells, that GVHD morbidity and overall mortality are
reduced in hosts receiving 47
 donor T cells. Further analysis
demonstrated reduced T cell inﬁltration of the intestines and less
intestinal GVHD in recipients of 47
 donor T cells, while
inﬁltration other GVHD target organs (skin, thymus) was similar
to that seen in recipients of 47 donor T cells. Concerns
remain however, that, in the setting of allogeneic hematopoietic
stem cell transplantation (HSCT), using a monoclonal antibody
blocking the 4 subunit could interfere with stem cell engraftment.
We hypothesized that blocking only the 7 subunit would also
produce less intestinal GVHD and less overall GVHD morbidity
and mortality, while alleviating concerns regarding stem cell en-
graftment. We used several models with MHC class I and II
disparity, comparing allografts containing donor T cells from ei-
ther wild type mice or from 7
/
 mice. To assess whether
7
/
 T cells have an intact alloreactive response in vivo, we
performed studies with CFSE-labeled donor T cells, which were
transferred into an irradiated allogeneic recipient. We observed no
differences in the fraction of alloreactive T cells or the kinetics of
alloreactive proliferation between recipients of 7
/
 vs. wild
type T cells. Recipients of donor 7
/
 T cells developed less
GVHD morbidity (as determined by clinical GVHD scoring) and
less GVHDmortality than those receiving wild type donor T cells.
In a graft-versus-tumor (GVT) model with P815, we found no
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